Cargando…
Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
OBJECTIVE: To review the pharmacological properties and the available clinical data of full length parathyroid hormone (PTH) in post-menopausal osteoporosis. SOURCES: A MEDLINE search was completed, together with a review of information obtained from the manufacturer and from the medicine regulatory...
Autor principal: | Jódar-Gimeno, Esteban |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684083/ https://www.ncbi.nlm.nih.gov/pubmed/18044089 |
Ejemplares similares
-
Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis
por: Pietrogrande, Luca
Publicado: (2010) -
Recombinant Human Parathyroid Hormone Related Protein 1-34 and 1-84 and Their Roles in Osteoporosis Treatment
por: Wang, Hua, et al.
Publicado: (2014) -
Identifying and Managing Patients at High Risk for Fractures: Conclusions from the Second Spanish Multidisciplinary Forum—Parathyroid Hormone Use in Osteoporotic Patients at High Risk for Fractures
por: Gimeno, Esteban Jódar
Publicado: (2012) -
Parathyroid Hormone Disturbances in Postmenopausal Women with Distal Forearm Fracture
por: Wihlborg, Axel, et al.
Publicado: (2021) -
Efficacy and safety of recombinant human parathyroid hormone (1–34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis
por: Deng, Jing, et al.
Publicado: (2018)